Sequential High-Dose Dexamethasone and Response Adapted PAD (Bortezomib, Adriamycin, Dexamethasone) or VAD (Vincristine, Adriamycin, Dexamethasone) Chemotherapy Followed by High-Dose Therapy with ASCT for Newly Diagnosed Multiple Myeloma; Open-Labeled, Multicenter Phase 2 Study (KMM-94 Study)-Interim Analysis.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Jae Hoon | - |
dc.contributor.author | Hong, Junshik | - |
dc.contributor.author | Kim, Jin Seok | - |
dc.contributor.author | Cheong, June-Won | - |
dc.contributor.author | Suh, Cheolwon | - |
dc.contributor.author | Kim, Kihyun | - |
dc.contributor.author | Kim, Yang Soo | - |
dc.contributor.author | Lee, Se-Ryeon | - |
dc.contributor.author | Bae, Sung Hwa | - |
dc.contributor.author | Joo, Young-Don | - |
dc.contributor.author | Lee, Sang Min | - |
dc.contributor.author | Eom, Hyeon Seok | - |
dc.contributor.author | Park, Eunkyung | - |
dc.contributor.author | Yoon, Sung-Soo | - |
dc.contributor.author | Kim, Inho | - |
dc.contributor.author | Kwak, Jae-Yong | - |
dc.contributor.author | Min, Chang-Ki | - |
dc.contributor.author | Kim, Jeong-A | - |
dc.contributor.author | Park, Moo-Rim | - |
dc.contributor.author | Kim, Sung Hyun | - |
dc.contributor.author | Kang, Hye Jin | - |
dc.contributor.author | Kim, Min Kyoung | - |
dc.contributor.author | Kim, Hawk | - |
dc.contributor.author | Mun, Yeung-Chul | - |
dc.contributor.author | Kim, Hoon-Gu | - |
dc.contributor.author | Lee, Moon Hee | - |
dc.date.available | 2020-02-29T04:45:35Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2012-11-16 | - |
dc.identifier.issn | 0006-4971 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/16005 | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | AMER SOC HEMATOLOGY | - |
dc.relation.isPartOf | BLOOD | - |
dc.title | Sequential High-Dose Dexamethasone and Response Adapted PAD (Bortezomib, Adriamycin, Dexamethasone) or VAD (Vincristine, Adriamycin, Dexamethasone) Chemotherapy Followed by High-Dose Therapy with ASCT for Newly Diagnosed Multiple Myeloma; Open-Labeled, Multicenter Phase 2 Study (KMM-94 Study)-Interim Analysis. | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000314049601157 | - |
dc.identifier.doi | 10.1182/blood.V120.21.3106.3106 | - |
dc.identifier.bibliographicCitation | BLOOD, v.120, no.21 | - |
dc.citation.title | BLOOD | - |
dc.citation.volume | 120 | - |
dc.citation.number | 21 | - |
dc.contributor.affiliatedAuthor | Lee, Jae Hoon | - |
dc.contributor.affiliatedAuthor | Hong, Junshik | - |
dc.type.docType | Meeting Abstract | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.